Enfortumab vedotin monotherapy (urothelial carcinoma)

Name: Enfortumab vedotin monotherapy (urothelial carcinoma) - OpenOnco
License: https://creativecommons.org/licenses/by/4.0/

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ENFORTUMAB-VEDOTIN`

ID	`REG-EV-MONO-UROTHELIAL`
Type	Regimen
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	None declared
Sources	None declared

Used By

Indication

IND-UROTHELIAL-2L-EV - IND-UROTHELIAL-2L-EV